GLAXF GSK plc

NEUTRAL Impact: 2/10 6-K
Horizon days Filed Jun 1, 2026 Processed 11d 18h ago SEC 0001654954-26-005584
Notable filing: 6-K
Latest settled — T+5d ⚠ clustered
GLAXF ▲ +1.69% at T+5d
NEUTRAL call ✓ call won +1.69% · α vs SPY +4.44% · entry $24.25 → $24.66
Next anchor: T+20d in 17d
Currently $26.63 · +9.81% from $24.25 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
-1.28%
call -1.28% · α -1.42%
$23.94
settled 11d ago
T+5d
+1.69%
call +1.69% · α +4.44%
$24.66
settled 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

GSK plc disclosed routine open-market share repurchases totaling 1,248,271 ordinary shares between May 26-29, 2026, as part of its existing buyback program. The purchases were executed through a non-discretionary broker agreement at volume-weighted average prices ranging from 1,899.95 GBp to 1,932.82 GBp per share. This is a standard capital return disclosure with no material new information for traders.

Actionable Insight

This is a routine buyback disclosure with no new program authorization or change in pace. Monitor GSK's next quarterly filing for any update on buyback program size or duration. No immediate trading action warranted.

Key Facts

  • GSK purchased 1,248,271 ordinary shares over four trading days (May 26-29, 2026) at VWAPs between 1,899.95 GBp and 1,932.82 GBp.
  • Total shares bought since program start on May 11, 2026: 4,590,420 ordinary shares.
  • Post-purchase, GSK holds 265,968,706 shares in treasury (6.57% of voting rights) and has 4,050,256,108 shares outstanding.
  • Purchases were made under a non-discretionary agreement with Citigroup Global Markets Limited dated May 8, 2026.

Financial Impact

Approximately £23.9 million deployed in the reported week (1,248,271 shares × ~£19.15 average VWAP). Cumulative program spend since May 11: ~£88 million.

share counttreasury sharesvoting rights

Risk Factors

  • Buyback pace may slow if GSK prioritizes other capital allocation (M&A, R&D spend).
  • No change to underlying business fundamentals — share price impact from buybacks is typically modest and gradual.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
41% bullish (32 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005584
Document: 0001654954-26-005584-index-headers.html0001654954-26-005584
Document: 0001654954-26-005584-index.html0001654954-26-005584
Document: 0001654954-26-005584.txt0001654954-26-005584
51 reports for GLAXF
Performance horizon
42% Hit rate 5 of 12 directional calls best @ T+5▲ +7.60%Apr 1, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
Type Now
Jun 10, 2026
2d ago
6-K
NEUTRAL ★ 1/10
$23.54 awaiting T+5awaiting T+5$26.63 (+13.13%)
Jun 9, 2026
3d ago
6-K
NEUTRAL ★ 1/10
$24.66 awaiting T+5awaiting T+5$26.63 (+7.99%)
Jun 9, 2026
3d ago
6-K
BULLISH ★ 7/10
$24.66 awaiting T+5awaiting T+5$26.63 (+7.99%)
Jun 1, 2026
11d ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.63 (+9.81%)
Jun 1, 2026
11d ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.63 (+9.81%)
May 28, 2026
15d ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.63 (+8.34%)
May 27, 2026
16d ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.63 (+4.15%)
May 26, 2026
17d ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.63 (+4.43%)
May 26, 2026
17d ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.63 (+4.43%)
May 22, 2026
21d ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.63 (+2.42%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (53h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access